PDS Biotechnology 5.29M share Spot Secondary priced at $8.50 » 09:0306/1506/15/21
The deal priced at low…
The deal priced at low end of $8.50-$9.00 range. Cantor Fitzgerald is acting as sole book running manager for the offering.
Fly Intel: After-Hours Movers » 18:4106/1406/14/21
BBCP, PDSB, VRM, CCCC, CBRL, ABR, FUSN
PDS Biotechnology Spot Secondary price range $8.50-$9.00 » 16:3006/1406/14/21
Cantor Fitzgerald is…
Cantor Fitzgerald is acting as sole book running manager for the offering.
PDS Biotechnology files to sell common stock, no amount given » 16:0306/1406/14/21
Cantor Fitzgerald &…
Cantor Fitzgerald & Co. is acting as sole bookrunner for the offering.
|Over a week ago|
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer » 07:3606/0906/09/21
Oppenheimer analyst Leland Gershell raised the firm's price target on PDS Biotechnology to $25 from $12 and keeps an Outperform rating on the shares. The analyst notes that following the positive meeting abstract, an oral ASCO presentation of expanded clinical results in advanced, heavily-pretreated HPV-associated cancers strengthens PDS0101's treatment prospects for these challenging malignancies as well as further supports Versamune platform potential for broader cancer immunotherapy. Looking ahead, the data bolsters his confidence in '0101's prospects with Keytruda in the first-line treatment of recurrent/metastatic head and neck cancer, for which initial results could become available by year-end. Together with the ongoing cervical cancer trial, which adds PDS0101 to standard-of-care cisplatin/radiation therapy, these three sets of clinical study results should collectively establish a solid foundation to inform key elements of registrational trial design as well as drive interest in PDS's technology among larger oncology players, Gershell contends.
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners » 07:0506/0906/09/21
Alliance Global Partners…
Alliance Global Partners analyst James Molloy raised the firm's price target on PDS Biotechnology to $18 from $6.50 and keeps a Buy rating on the shares after the company reported additional data from its ongoing PDS0101 Phase 2 triple combination trial in HPV-related cancers at ASCO. He has lowered his discount rate on expected future royalty payments and is now including a separate valuation for PDSB0101 given the recent promising HPV triple combination data and "promising results" from PDS' proprietary Versamune platform, Molloy tells investors.
PDS Biotechnology price target raised to $15 from $11 at Chardan » 19:3706/0806/08/21
Chardan analyst Geulah…
Chardan analyst Geulah Livshits raised the firm's price target on PDS Biotechnology to $15 from $11 and keeps a Buy rating on the shares. The data from an NCI-led trial of PDS0101 with NHS-IL12 and M7824 presented at ASCO yesterday thus far appears to diverge in a meaningful way from relevant standard-of-care benchmarks in both immune checkpoint inhibitor (ICI)-naive and post-ICI settings, and also provides a positive read-across to the VERSATILE-002 study of PDS0101 + Keytruda in HPV16+ head and neck cancer, the analyst tells investors in a research note.
PDS Biotechnology presents interim data from Phase 2 trial on PDS0101 » 06:0406/0806/08/21
PDS Biotechnology announced the presentation of interim data from the Phase 2 trial led by the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, at the American Society of Clinical Oncology 2021 Annual Meeting. The Phase 2 trial studies PDS0101, or Versamune-HPV16, in combination with two investigational immune-modulating agents: bintrafusp alfa, or M7824, a bifunctional "trap" fusion protein targeting TGF-beta and PD-L1, and NHS-IL12, or M9241, a tumor-targeting immunocytokine. PDS0101 is an immunotherapy candidate designed to treat cancers caused by infection with HPV16, or HPV16-positive cancers, by activating the immune system to produce in vivo CD8+ T-cells to target and kill tumors that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing. The presentation includes data from a total of 25 patients with data available as of the time of presentation submission, an update on the data previously reported for the original fourteen HPV16-positive patients who were in the subject of the abstract published on May 19th; an additional seven HPV16-negative patients who were not discussed in the abstract, and an additional four HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.
PDS Biotechnology Corp trading resumes 15:3606/0706/07/21
PDS Biotechnology Corp trading halted, volatility trading pause 15:3106/0706/07/21